Viking Therapeutics Ownership
| VKTX Stock | USD 54.51 1.09 2.04% |
Shares in Circulation | First Issued 2012-12-31 | Previous Quarter 110.4 M | Current Value 110.9 M | Avarage Shares Outstanding 51.4 M | Quarterly Volatility 35.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Viking |
Viking Stock Ownership Analysis
About 75.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.94. Viking Therapeutics had not issued any dividends in recent years. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company was incorporated in 2012 and is headquartered in San Diego, California. Viking Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. For more information please call Brian Lian at 858 704 4660 or visit https://www.vikingtherapeutics.com.Besides selling stocks to institutional investors, Viking Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Viking Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Viking Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Viking Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Viking Therapeutics Insider Trades History
About 6.0% of Viking Therapeutics are currently held by insiders. Unlike Viking Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Viking Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Viking Therapeutics' insider trades
Viking Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viking Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viking Therapeutics backward and forwards among themselves. Viking Therapeutics' institutional investor refers to the entity that pools money to purchase Viking Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alliancebernstein L.p. | 2024-06-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.2 M | Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | International Assets Investment Management, Llc | 2024-09-30 | 1 M | Westfield Capital Management Company, Lp | 2024-09-30 | 930.4 K | Perpetual Ltd | 2024-06-30 | 816.8 K | Hood River Capital Management Llc | 2024-09-30 | 815.7 K | Clearbridge Advisors, Llc | 2024-09-30 | 738.6 K | Millennium Management Llc | 2024-06-30 | 723 K | Fmr Inc | 2024-09-30 | 16.6 M | Vanguard Group Inc | 2024-09-30 | 10.2 M |
Viking Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viking Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viking Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viking Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viking Therapeutics Outstanding Bonds
Viking Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viking Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viking bonds can be classified according to their maturity, which is the date when Viking Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US92682RAA05 Corp BondUS92682RAA05 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Viking Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 23rd of May 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.